...
首页> 外文期刊>Transplant infectious disease: an official journal of the Transplantation Society >Immunosuppressive therapy and infection after kidney transplantation.
【24h】

Immunosuppressive therapy and infection after kidney transplantation.

机译:肾脏移植后的免疫抑制治疗和感染。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The role of immunosuppressive drugs in the development of infection in transplant recipients has been poorly analyzed. OBJECTIVE: To evaluate the possible association between infection and immunosuppression regimens in a large cohort of renal transplant recipients. METHODS: All renal transplant recipients included in the RESITRA prospective cohort from August 2003 to February 2005 with a minimum follow-up of 3 months were studied. An intention-to-treat analysis was performed and patients were analyzed in groups according to the type of induction and initial maintenance therapy. Viral, bacterial, and fungal infections occurring during this period were evaluated. RESULTS: A total of 1398 renal transplant recipients were studied. A maintenance regimen containing sirolimus was independently associated with a lower risk of cytomegalovirus (CMV) infection (odds ratio [OR], 0.16; 95% confidence interval [CI], 0.05-0.54) and with a higher rate of surgical site infection (OR, 3.21; 95% CI, 1.26-8.21). Excluding treatment used for acute rejection episodes, no other factors related to the immunosuppression regimens were associated with the development of bacteremia, urinary infections, pneumonia, or other infections. CONCLUSION: The use of sirolimus as maintenance therapy in kidney recipients is associated with a low rate of CMV infection and with a higher risk of surgical site infection.
机译:背景:对免疫抑制药物在移植受体感染发展中的作用进行了很少的分析。目的:评估大批肾移植受者中感染与免疫抑制方案之间的可能联系。方法:研究了2003年8月至2005年2月纳入RESITRA前瞻性队列的所有肾移植受者,至少随访3个月。进行意向性治疗分析,并根据诱导和初始维持治疗的类型对患者进行分组分析。对在此期间发生的病毒,细菌和真菌感染进行了评估。结果:共研究了1398例肾移植受者。包含西罗莫司的维持方案与降低巨细胞病毒(CMV)感染的风险独立相关(比值比[OR]为0.16; 95%置信区间[CI]为0.05-0.54)和较高的手术部位感染率(OR ,3.21; 95%CI,1.26-8.21)。除了用于急性排斥反应的治疗方法外,没有其他与免疫抑制方案有关的因素与菌血症,尿路感染,肺炎或其他感染的发生有关。结论:在肾脏接受者中使用西罗莫司作为维持治疗与CMV感染率低和手术部位感染的风险较高有关。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号